Other News To Note
Dyax Corp., of Burlington, Mass., and Novellus Biopharma AG, of Bogota, Colombia, inked a partnership for the development and commercialization of hereditary angioedema drug Kalbitor (ecallantide) in select regions in Latin America, including Argentina, Brazil, Chile, Colombia, Mexico and Venezuela.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.